We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Probe Detects Breast Cancer Margins

By HospiMedica International staff writers
Posted on 03 Jul 2012
A new device uses radiofrequency (RF) spectroscopy to differentiate tissue types, helping surgeons assure that all cancerous tissue is removed around a breast cancer site. More...


The MarginProbe system enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The device works by emitting an RF electric field and sensing the returning signal from the tissue under evaluation. The device is based on the fact that tumors exhibit greater vascularization, a different polarization of the cell membrane, enlarged nucleus volume, rapid copying of DNA, rapid growth of new blood vessels (angiogenesis), and a decrease in the connectivity from one cell to another.

Since these and other and other anatomical differences are evident when compared to healthy tissue, the electromagnetic signature is different as well. The device captures these minute differences in electromagnetic properties via a disposable probe unit that houses a highly responsive fringe field sensor (FFS) that both emits the precisely controlled electromagnetic field and captures the tissue response. The surgeon runs a series of measurements on each margin, collecting data for the entire specimen.

An external console houses proprietary software that captures the signal, compares it to the internal database, and characterizes the specimen, reporting results on the high-resolution display. The display lists each reading sequentially, which allows for grouping measurements from the same margin. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, significantly reducing the potential for positive margins remaining after the initial lumpectomy. The MarginProbe System is a product of Dune Medical (Framingham, MA, USA), and is pending approval by the US food and Drug Administration (FDA).

“We believe that the MarginProbe System will give surgeons a powerful tool in their fight against breast cancer and provide women a substantially better chance of avoiding additional surgeries,” said Dan Levangie, CEO of Dune Medical. “We will work closely with the FDA to complete the approval process and intend to launch the MarginProbe System in the U.S. immediately thereafter.”

RF Spectroscopy is concerned with the measurement of the intervals between atomic or molecular energy levels that are separated by radio frequency wavelengths. It is used in such industries as the semiconductor, pharmaceutical, aerospace, and fuel cell fields.

Related Links:
Dune Medical


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.